Dr. I.M. Bennani-Baiti, Executive Editor of Clinical Cancer Epigenetics

I.M. Bennani-Baiti

Executive Editor,
Clinical Cancer Epigenetics


Dr. I.M. Bennani-Baiti currently serves as the Executive Editor of Clinical Cancer Epigenetics. Dr. Bennani-Baiti has longstanding interests in pediatric cancer, epigenetics, epigenomics, chemistry, and biomathematics. He has extensive experience in reviewing and editing research papers, serving since 2009 as the Executive Editor or Editor to 9 biomedical journals, and as a Reviewer to more than a dozen other journals. A University of Pennsylvania School of Medicine Human Genetics Fellow, he is also a Howard Hughes scholar who served on the Faculty of St. Louis University School of Medicine under the chairmanship of Dr. William Sly, a member of the National Academy of Sciences, USA, who characterized the syndrome named after him. Other tenures include the Memorial Sloan-Kettering Cancer Center in New York alongside Dr. Mark Ptashne, Lasker Award laureate and member of the National Academy of Sciences, USA, first under the leadership of Dr. Paul Marks, member of the National Academy of Sciences, USA, and later Dr. Harold Varmus, former director of the National Institute of Health (NIH) and of the National Cancer Institute (NCI), Lasker Award and Nobel Prize laureate, and member of the National Academy of Sciences, USA. Dr. Bennani-Baiti is a member of the Society for Mathematical Biology, the American Chemical Society, and the AACR Pediatric Cancer Working Group. He is also a member of the New York Academy of Sciences, USAFellow and Member of the Council of the Royal Society of Medicine, and President of the Cancer Epigenetics Society.

Most Recent Articles:

Liersch-Löhn B et al. Differential protein expression and oncogenic gene network link tyrosine kinase Ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers. International Journal of Cancer 138: 1220-1231; Mar 1, 2016.

Toegel S et al. Galectin-1 couples glycobiology to inflammation in osteoarthritis through the activation of an NF-kB-regulated gene network. Journal of Immunology 196: 1910-1921; Feb 15, 2016.

Bennani-Baiti N & Bennani-Baiti IM. Cancer bioinformatic methods to infer meaningful data from small-size cohorts. Cancer Informatics 14: 131-139; Nov 2, 2015.

Bennani-Baiti B et al. Inflammation modulates RLIP76/RALBP1 electrophile-glutathione conjugate transporter and housekeeping genes in human blood brain barrier endothelial cells. PLoS One 10: e0139101; Sep 25, 2015.

Most Read Reviews:

Bennani-Baiti IM. Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer. Breast Cancer Res. 14: 112.

Bennani-Baiti B & Bennani-Baiti IM. Gene symbol precision. Gene 491: 103-109.

Bennani-Baiti IM. Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis. Epigenomics 3: 715-732.

Most Cited Papers:

Richter GHS et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuroectodermal differentiation. Proc. Natl. Acad. Sci. USA. 106: 5324-5329.

Torigoi E et al. Chip interacts with diverse homeodomain proteins and potentiates Bicoid activity in vivo. Proc. Natl. Acad. Sci. USA. 97: 2686-2691.

Bennani-Baiti IM et al. HS I,II of the human growth hormone locus control region is a major developmental activator of somatotrope gene expression. Proc. Natl. Acad. Sci. USA. 95: 10655-10660.

Bennani-Baiti IM et al. Notch signalling is off and is uncoupled from HES1 expression in Ewing’s sarcoma. Journal of Pathology 225: 353-363.

Bennani-Baiti IM et al. Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing’s sarcoma. Clinical Cancer Research 16: 3769-3778.